Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at 95 Park Drive in Milton Park, one of the leading science and technology communities in Europe.
Evotec’s latest expansion space, which totals 43,141 sq ft across three floors is in addition to the 16,823 sq ft at 90 Park Drive it took in September 2020.
Evotec has had a presence at Milton Park ever since the company’s merger with Oxford Asymmetry International plc in 2000. Oxford Asymmetry International had been based at Milton Park since 1989 and started in one of the original ex-MOD depot buildings.
This expansion makes Evotec one of the largest occupiers on the Park alongside Immunocore and Adaptimmune, all of which started life at Milton Park as University of Oxford spinouts.
Christophe Muller, PhD, head of Evotec’s Milton Park site and EVP global head of business development, said: “We are proud to be growing our Milton Park presence into the fully integrated, co-located drug discovery and development centre we now call ‘Dorothy Crowfoot Hodgkin Campus’. 95 Park Drive gives us the high-quality space we need to further strengthen our biology capabilities and expertise on-site, bringing together all the key functions required to provide an accelerated path for our partners, from discovery to commercial manufacture.”
Philip Campbell, commercial director, MEPC commercial director, Milton Park said: “95 Park Drive is a prominent building which will provide Evotec with much-needed new office and lab space as they continue their impressive growth plans. We continue to see strong demand from the global health and life sciences sectors looking to be based in Oxfordshire, for satellite, expansion or relocation space.”
The terms of the deal remain confidential.